


VVD-118313

Cat. No.:	HY-151385
CAS No.:	2875046-27-6
Molecular Formula:	C ₁₉ H ₂₂ Cl ₂ N ₂ O ₃ S
Molecular Weight:	429.36
Target:	JAK; IFNAR; Interleukin Related; STAT
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; Immunology/Inflammation
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (232.90 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3290 mL	11.6452 mL	23.2905 mL
		5 mM	0.4658 mL	2.3290 mL	4.6581 mL
10 mM		0.2329 mL	1.1645 mL	2.3290 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	VVD-118313 (compound 5a) is a potent, selective JAK1 inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer ^[1] . VVD-118313 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC₅₀ & Target	JAK1

In Vitro

VVD-118313 (compound 5a; 0.01-10 μ M; 3 h; primary human PBMCs) inhibits JAK1 by engagement of C817 and JAK2 by engagement of C838. VVD-118313 inhibits cysteine reactivity in a dose-dependent manner^[1].
VVD-118313 (2 μ M, 2h) blocks IFN α -stimulated STAT1 and IL-6-stimulated STAT3 phosphorylation in WT- or C810A-JAK1-expressing 22Rv1 cells. VVD-118313 also blocks the constitutive phosphorylation of WT- and C810A-JAK1^[1].
VVD-118313 (0.01-10 μ M) selectively inhibits JAK1 signaling in primary human immune cells. VVD-118313 inhibits JAK1-dependent IFN α -pSTAT1, IL-6-pSTAT3, and IL-2-pSTAT5 pathways in human PBMCs in a dose-dependent manner^[1].
VVD-118313 (0.1-0.4 μ M; 24 h) inhibits T-cell activation induction. VVD-118313 inhibits the activation of human T cells co-stimulated with α CD3/ α CD28 by a reduction in the proportion of CD25⁺ T cells. VVD-118313 blocks the secretion of the Th1-polarizing cytokine IFN γ and increases the production of IL-2^[1].
VVD-118313 (0.1-0.5 μ M; 2 h) inhibits on the production of pro-inflammatory cytokines and chemokines. VVD-118313 suppresses the induction of several pro-inflammatory chemokines, including CCL2/MCP-1, CXCL10/IP-10, and CCL4/MIP-1 β ^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	22Rv1 cells
Concentration:	0.01, 0.1, and 1 μ M
Incubation Time:	2 hours
Result:	Showed labeling of recombinant WT-JAK1 and C810A-JAK1, but not C817A-JAK1.

Western Blot Analysis^[1]

Cell Line:	22Rv1 cells
Concentration:	2 μ M
Incubation Time:	2 hours
Result:	Inhibited WT- and C810A-JAK1 phosphorylation with even greater potency than STAT1/STAT3 phosphorylation.

In Vivo

VVD-118313 (compound 5a; 25-50 mg/kg; i.h.; once) inhibits JAK1 signaling in TYK2 knockout mice^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	TYK2 knockout mice ^[1]
Dosage:	25 and 50 mg/kg
Administration:	Subcutaneous injection; once
Result:	Revealed 75% engagement of JAK1_C816 at 25 and 50 mg/kg, while other JAK1 cysteines were unaffected in reactivity.

REFERENCES

[1]. Kavanagh ME, et, al. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine. Nat Chem Biol. 2022 Sep 12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA